Skip to main content

Advertisement

Log in

Management of inoperable carcinoma with particular reference to the use of cytoxan: Preliminary report

  • Published:
Diseases of the Colon & Rectum

Summary and Conclusions

A preliminary report in the use of Cytoxan in six patients with inoperable, far-advanced or recurrent adenocarcinoma of the large bowel is presented.

Two of the six patients had received the drug long enough for evaluation and both had apparent beneficial effects.

Further study of the effect of the drug in cases of carcinoma of the large bowel is required before significant conclusions can be reached.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Arnold, Herbert, Friedrich Bourseaux and Norbert Brock: Neuartige Krebs-Chemotherapeutika aus der Gruppe der zyklischen N-Lost-Phosphamidester. Naturwissenschnften.45: 64, 1958.

    Article  CAS  Google Scholar 

  2. Baumann, E.: Vorläufige Mitteilung über die Behandlung maligner Tumoren mit einem neuen N-Lost-Phosphamidester. Medizinische.14: 659, 1959.

    Google Scholar 

  3. Brock, N. Zur pharmakologischen Charackterisierung zyklischer N-Lost-Phosphamidester als Krebs-Chemotherapeutica. Arzneimittel-Forschung.8: 1, 1958.

    PubMed  CAS  Google Scholar 

  4. Brock, N., and H. Wilmanns: Wirkung eines zyklischen N-Lost-Phosphamidesters auf experimentell erzeugte Tumoren der Ratte. Deutsche med. Wchnschr.83: 453, 1958.

    CAS  Google Scholar 

  5. Coggins, P. R., R. G. Ravdin, and S. H. Eisman: Clinical pharmacology and preliminary evaluation of Cytoxan (Cyclophosphamide). Cancer Chemotherapy Reports. U. S. Dept. of Health, Education and Welfare, Public Health Service, no. 3, June, 1959, p. 9.

  6. Deddish, M. R.: Surgical procedures for carcinoma of the left colon and rectum, with five-year end results following abdominopelvic dissection of lymph nodes. Am. J. Surg.99: 188, 1960.

    Article  PubMed  CAS  Google Scholar 

  7. Dunphy, J. E.: Quoted by Crile, George, Jr.: Cancer and Common Sense. New York, Viking Press, 1955, p. 101.

    Google Scholar 

  8. Gross, Rudolf and Klaus Lambers: Erste Erfahrungen in der Behandlung maligner Tumoren mit einem neuen N-Lost-Phosphamidester. Deutsche med. Wchnschr.83: 458, 1958.

    Article  CAS  Google Scholar 

  9. Lambers, K.: Behandlung der Lymphosarkome. Ärztl. Wchnschr.13: 692, 1958.

    CAS  Google Scholar 

  10. Mead Johnson & Company Brochure.

  11. Petrides, P. and C. Moncke: Die Beeinflussung der Hamatopoese bei der Therapie von malignen Tumoren und Hamoblastosen mit einem N-Lost-Phosphamidester (Endoxan). Mitteilungsdienst der Gesellschaft zur Bekampfung der Krebskrankheiten Nordrhein Westfalen e.V., 2, no. 6, October, 1958.

  12. Saitmacher, Heinz: Klinischer Erfahrungsbericht über ein neues Zytostatikum (Endoxan). Strahlentherapie.107: 94, 1958.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Read at the meeting of the Pennsylvania Proctologic Society, May 18, 1960, Philadelphia, Pennsylvania.

Cytoxan is distributed in this country by Mead Johnson & Company.

About this article

Cite this article

Nuguid, T.P., Bacon, H.E. Management of inoperable carcinoma with particular reference to the use of cytoxan: Preliminary report. Dis Colon Rectum 4, 62–66 (1961). https://doi.org/10.1007/BF02616689

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02616689

Keywords

Navigation